Amitifadine

Drug Profile

Amitifadine

Alternative Names: Amitifadine hydrochloride; DOV-21947; EB-1010

Latest Information Update: 06 Jun 2013

Price : $50

At a glance

  • Originator DOV Pharmaceutical
  • Developer Euthymics Bioscience
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Major depressive disorder
  • Discontinued Obesity

Most Recent Events

  • 30 May 2013 Interim efficacy data from a phase IIb/IIIa trial in second-line Major depressive disorder released by Euthymics
  • 15 Oct 2012 Discontinued - Phase-I for Obesity in USA (PO)
  • 11 Oct 2012 Euthymics Bioscience completes enrolment in the phase IIb/IIIa TRIADE trial for Major depressive disorder in USA (NCT01318434)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top